A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors
{{output}}
Background AT-101 is a BH3 mimetic that inhibits the heterodimerization of Bcl-2, Bcl-xL, Bcl-W, and Mcl-1 with pro-apoptotic proteins, thereby lowering the threshold for apoptosis. This phase I trial investigated the MTD of AT-101 in combination with paclitax... ...
